CT52923CT52923
MedChemExpress (MCE)
HY-148514
205256-55-9
98.58%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC50 value of 100 to 200 nM[1]. CT52923 (0.01-30 μM
24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC50 of 64 and 280 nM, respectively[1].
CT52923 (oral
5, 15, 30, and 50 mg/kg
twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat[1].
| | | |
| | | | | |
[1]. J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep
298(3):1172-8. [Content Brief]